Empowering Patients With Myeloma Through Resources

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according to Diane Moran, RN, MA, EdM.